Deerfield Management Company, L.P. (Series C) Chimerix Inc Transaction History

Deerfield Management Company, L.P. (Series C)

$4.76 Billion
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 15, 2021	SELL	$5.94 - $8.75 $10.8 Million - $15.9 Million	-1,816,221 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.76 - $11.25 $8.65 Million - $20.4 Million	1,816,221 New	1,816,221 $17.5 Million

Others Institutions Holding CMRX

# of Institutions

Shares Held

36.8M

Call Options Held

72.2K

Put Options Held

169K

Ra Capital Management, L.P. Boston, MA

8.8M
Shares

$8.54 Million
0.12% of portfolio
Monaco Asset Management Sam

4.38M
Shares

$4.25 Million
0.63% of portfolio
Vanguard Group Inc Valley Forge, PA

4.35M
Shares

$4.22 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

2.22M
Shares

$2.16 Million
0.03% of portfolio
Acadian Asset Management LLC Boston, MA

2.17M
Shares

$2.11 Million
0.01% of portfolio

View Full List

About CHIMERIX INC

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

More about CMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account